参考文献/References:
[1] PAUL B，KANG Shuqi，ZHENG Zhihong，et al. The challenges of checkpoint inhibition in the treatment of multiple myeloma[J]. Cellular Immunology, 2018, 334: 87-98.
[2] ROBAK P, DROZDZ I, SZEMRAJ J, et al. Drug resistance in multiple myeloma[J].Cancer Treat Rev，2018, 70:199-208.
[3] GUPTA N, SHARMA A, SHARMA A. Emerging biomarkers in multiple myeloma: a review [J]. Clinica Chimica Acta, 2020, 503: 45-53.
[4] 盘国雄, 谭才燕, 何嘉颖, 等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志, 2018, 33(1): 72-76． PAN Guoxiong, TAN Caiyan, HE Jiaying, et al. Serum lncrnA PCAT-1 expression level of patients with multiple myeloma and clinical value [J]. Journal of Modern Laboratory Medicine, 2018, 33(1): 72-76．
[5] KEIR M E,BUTTE M J, FREEMAN G J, et al. PD-1 and its ligands in tolerance and immunity[J]. Annual Review of Immunology,2008, 26:677-704.
[6] CHAMOTO K, AL-HABSI M, HONJO T. Role of PD-1 in immunity and diseases[J]. Current Topics in Microbiology and Immunology, 2017, 410: 75-97.
[7] KUOL N, STOJANOVSKA L, NURGALI K A. PD-1/PD-L1 in disease[J]. Immunotherapy, 2018, 10(2): 149-161.
[8] JELINEK T, PAIVA B, HAJEK R. Update on PD-1/PD-L1 inhibitors in multiple myeloma[J]. Frontiers in Immunology, 2018, 9: 2431.
[9] ROSSILLE D, AZZAOUI I, FELDMAN A L, et al. Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients[J]. Leukemia, 2017, 31(4): 988-991.
[10] HAYASHI H, NAKAGAWA K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer[J]. International Journal of Clinical Oncology, 2020, 25(5): 818-830.
[11] 李腾达, 陈燕, 谷明莉, 等.PD-L1在原发性胆汁性肝硬化患者外周血单个核细胞中的变化及意义[J].现代检验医学杂志, 2017, 32(5):1-3. LI Tengda, CHEN Yan, GU Mingli, et al. Change of PD-L1 in peripheral blood mononuclear cells of patients with primary biliary cirrhosis and its significance [J]. Journal of Modern Laboratory Medicine, 2017, 32(5): 1-3．
[12] HALLETT W H, JING Weiqing, DROBYSKI W R. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade[J]. Biology of Blood and Marrow Transplantation, 2011, 17(8): 1133-1145.
[13] DHODAPKAR M V, SEXTON R, DAS R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy[J]. Blood, 2015, 126(22): 2475-2478.
[14] CHEN Yongjing,WANG Qin, SHI Bimin, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1 + cell lines[J]. Cytokine, 2011, 56(2): 231-238.
[15] WANG Liang, WANG Hua, CHEN Hao, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma[J]. Oncotarget, 2015, 6(38): 41228-41236.
[16] TAMURA H, ISHIBASHI M, SUNAKAWA-KII M, et al.PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma[J]. Cancers(Basel), 2020, 12(4): 924.
[17] TREMBLAY-LEMAY R,RASTGOO N,CHANG Hong. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway[J].Journal of Hematology & Oncology, 2018, 11(1): 46.
相似文献/References:
[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies
Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis,
Serum Protein Electrophoresis and Immunoglobulins and Light Chain
Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels
in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(02):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width
in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes
in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients
with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(02):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma
and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute
Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(02):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(02):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]徐海燕,陆学东.多发性骨髓瘤早期实验诊断相关新兴生物标志物的最新研究进展[J].现代检验医学杂志,2021,36(05):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
XU Hai-yan,LU Xue-dong.Recent Research Rrogress of Novel Biomarkers for Early ExperimentalDiagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(02):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]